SURAKSHA2025-01-012025-03-31SURAKSHA2025-03-31SURAKSHA2024-03-31SURAKSHA2024-04-012025-03-31SURAKSHA2025-01-012025-03-31in-capmkt:OtherExpenses1MemberSURAKSHA2025-01-012025-03-31in-capmkt:OtherExpenses2MemberSURAKSHA2025-01-012025-03-31in-capmkt:OtherExpenses3MemberSURAKSHA2025-01-012025-03-31in-capmkt:OtherExpenses4MemberSURAKSHA2025-01-012025-03-31in-capmkt:OtherExpenses5MemberSURAKSHA2025-01-012025-03-31in-capmkt:OtherExpenses6MemberSURAKSHA2025-01-012025-03-31in-capmkt:OtherExpenses7MemberSURAKSHA2025-01-012025-03-31in-capmkt:OtherExpenses8MemberSURAKSHA2025-01-012025-03-31in-capmkt:OtherExpenses9MemberSURAKSHA2025-01-012025-03-31in-capmkt:OtherExpenses10MemberSURAKSHA2024-04-012025-03-31in-capmkt:OtherExpenses1MemberSURAKSHA2024-04-012025-03-31in-capmkt:OtherExpenses2MemberSURAKSHA2024-04-012025-03-31in-capmkt:OtherExpenses3MemberSURAKSHA2024-04-012025-03-31in-capmkt:OtherExpenses4MemberSURAKSHA2024-04-012025-03-31in-capmkt:OtherExpenses5MemberSURAKSHA2024-04-012025-03-31in-capmkt:OtherExpenses6MemberSURAKSHA2024-04-012025-03-31in-capmkt:OtherExpenses7MemberSURAKSHA2024-04-012025-03-31in-capmkt:OtherExpenses8MemberSURAKSHA2024-04-012025-03-31in-capmkt:OtherExpenses9MemberSURAKSHA2024-04-012025-03-31in-capmkt:OtherExpenses10MemberSURAKSHA2025-01-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss1SURAKSHA2025-01-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss2SURAKSHA2024-04-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss1SURAKSHA2024-04-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss2SURAKSHA2025-01-012025-03-31AuditorDomain1iso4217:INRiso4217:INRxbrli:shares544293SURAKSHANOTLISTEDINE877V01027SURAKSHA DIAGNOSTIC LIMITEDMain BoardEquity2024-04-012025-03-312025-05-282025-05-21INRLakhsQuarterlyFourth quarterSingle segmentDIAGNOSTIC2025-05-2814:00:002025-05-2818:30:00trueCash Flow IndirectDeclaration of unmodified opinion2025-01-012025-03-31AuditedConsolidated6509470008168000659115000884800000010203400020633000872880002685550005669900009212500009212500014708000570800020416000071709000000071709000-6340007107500073887000-217800073253000-218400010416200021.421.42001.421.421. The consolidated financial results for the quarter and financial year ended 31 March 2025 of Suraksha Diagnostic Limited the Holding Company and its subsidiary have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard Ind AS notified under Section 133 of the Companies Act 2013 as amended read with relevant rules thereunder and other accounting principles generally accepted in India and in accordance with Regulation 33 of the SEBI Listing Regulations 2015 as amended. The Holding company and subsidiaries together referred to as the group. <BR> 2. These financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors in their respective meeting held on 28 May 2025. These financial results for the year ended 31 March 2025 have been audited by the statutory auditor and they have issued an unmodified opinion. <BR> 3. The consolidated figures for the quarter ended 31 March 2025 are the balancing figures between the audited consolidated figures in respect of the full financial year and the published unaudited year to date consolidated figures up to the third quarter of the financial year. <BR> 4. The figures for the quarter ended 31 March 2024 are presented based on the information complied by the management in accordance with Ind AS and have not been subject to review or audit by the statutory auditors or by any other auditor. However the management has prepared the results for the said period by applying consistent accounting policies. <BR> 5. During the year ended 31 March 2025 the Holding company has completed an Initial Public Offering entirely as offer for sale of 19189330 equity shares by existing share holders with face value of Rs 2 and listed on both The National Stock Exchange of India Limited and Bombay Stock Exchange on 06 December 2024. <BR> 6. During the year ended 31 March 2025 0.0001 percent Compulsorily Convertible Preference Shares aggregating to 162859 preference shares of par value Rs 100 each were converted into 8955761 equity shares of par value of Rs 2 each in the Holding Company. <BR> 7. During the year ended 31 March 2025 the Nomination and Remuneration Committee of the Holding Company had approved grant of 208164 stock options to employees under the Suraksha Employee Stock Option Scheme 2024. The Company has accounted for these stock options in accordance with Ind AS 102 Share Based Payments. <BR> 8. The Group is primarily engaged in the business of diagnostic centres for carrying out various pathology and radiology services and as such there are no separate reportable segments as per Ind AS 108 Operating Segments. <BR> 9. During the quarter ended 31 March 2025 the Holding Company had entered into a Share Subscription Agreement for subscribing to 95841 equity shares of Rs 10 each representing 16.17 percent of the total equity share capital of Fetomat Wellness Private Limited. Subsequent to financial year ended 31 March 2025 the Holding Company had entered into Share Purchase Agreements with existing shareholders of Fetomat for acquisition of 277582 equity shares of Rs 10 each representing 46.83 percent of the total equity share capital of Fetomat resulting in Fetomat becoming a subsidiary of the Holding Company. <BR> 10. These financial results are also available on the Holding Company's website at www.surakshanet.com and on the stock exchange websites www.bseindia.com and www.nseinda.com. <BR> 11. Previous period's or year's figures have been regrouped or reclassified wherever necessary to conform to current period’s or year's classification. <BR> 2024-04-012025-03-31AuditedConsolidated2520900000384600002559360000295191000004289030008385300035297700098438300021453070004140530000414053000102938000133600010427400003097790000000309779000-2039000307740000318200000-8462000316202000-8462000104162000205.975.97005.975.97Impairment Loss8023000Advertisement12701000Rent expense13681000Power and fuel11105000Professional fees paid to doctors112495000Repairs and maintenance23363000Information technology expenses15616000Security and housekeeping charges15761000Commission to collection centers9451000other46359000Impairment Loss21858000Advertisement40420000Rent expense35502000Power and fuel72791000Professional fees paid to doctors426168000Repairs and maintenance82014000Information technology expenses53228000Security and housekeeping charges58998000Commission to collection centers34896000other158508000147137100010099300000757901000493400000100000000042691300043691300009160200028637140008048900001381230002246800017858900002530200036448200002655700047152800000333524200010416200020082350002112397000-100860002102311000287540000007122800007410340001022200054510000008057660002949800019674000116761000136435000226099000392032000338040001252000770000427165000001232931000333524200083853000-13706000-721220000-131590000-30941000001440000163420000352976000218580001036000091480000003245200002112000000264000032535300073940600000010581500006335910000100000000000001410000420240000000000000000000000355920000-2603000-39584100000000000-2811300002070010000636800001000000-240482000-27320000-27320002520000022468000Remeasurement gain/(loss) of net defined benefit plan-847000Income tax effect on above213000-634000Remeasurement gain/(loss) of net defined benefit plan-2725000Income tax effect on above686000-20390000000-634000-2039000AuditedtrueMSKA & ASSOCIATEStrue2027-07-31